Detailed Information

Cited 12 time in webofscience Cited 10 time in scopus
Metadata Downloads

A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudineopen access

Authors
Heo, JeongPark, Jun YongLee, Heon JuTak, Won YoungUm, Soon HoKim, Do YoungYoon, Ki TaePark, Soo YoungSeo, Yeon SeokHan, Kwang-HyubCho, MongAhn, Sang Hoon
Issue Date
Aug-2012
Publisher
INT MEDICAL PRESS LTD
Citation
ANTIVIRAL THERAPY, v.17, no.8, pp.1563 - 1570
Indexed
SCIE
SCOPUS
Journal Title
ANTIVIRAL THERAPY
Volume
17
Number
8
Start Page
1563
End Page
1570
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/30856
DOI
10.3851/IMP2277
ISSN
1359-6535
Abstract
Background: Growing numbers of chronic hepatitis B (CHB) patients in the Asia-Pacific region have failed first-line therapy with low genetic barrier drugs. This prospective, 96-week study investigated the antiviral efficacy, safety and tolerability of switching to entecavir versus maintaining lamivudine in CHB patients with a partial virological response to lamivudine. Methods: A total of 72 hepatitis B e antigen (HBeAg)-positive patients, with serum HBV DNA >= 60 IU/ml after >= 6 months lamivudine monotherapy were randomized 1:1 to receive either entecavir 1.0 mg/day, or continued lamivudine 100 mg/day. Results: Mean duration of prior lamivudine treatment was 15.1 months in the lamivudine-maintained patients and 16.1 months in the entecavir-switch patients, with mean baseline HBV DNA levels of 4.66 and 4.55 log(10) IU/ml, respectively. A greater proportion of entecavirswitch than lamivudine-maintained patients achieved undetectable HBV DNA at all time points (67.6% versus 11.4% at week 96; P<0.001). Entecavir-switch patients achieved a greater mean decrease in HBV DNA level by week 4, maintained through week 96. Entecavir-switch patients with baseline HBV DNA<5 log(10) IU/ml were more likely to achieve a virological response at week 96. A total of 6 (17.6%) entecavir-switch and 2 (5.7%) lamivudine-maintained patients achieved HBeAg loss, and 3 (8.8%) entecavir and 1 (2.9%) lamivudine patients achieved HBeAg seroconversion. Genotypic resistance to the assigned intervention emerged in 82.9% (29/35) of lamivudine-maintained patients, and in 3% (1/34) of entecavir-switch patients after 96 weeks. Conclusions: Switching to entecavir in patients with a partial virological response to lamivudine resulted in increased virological efficacy and lower rates of antiviral resistance than maintaining lamivudine.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Seo, Yeon Seok photo

Seo, Yeon Seok
Anam Hospital (Department of Gastroenterology and Hepatology, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE